Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Проект клинических рекомендаций по диагностике и лечению хронической инсомнии у взрослых
Проект клинических рекомендаций по диагностике и лечению хронической инсомнии у взрослых
Полуэктов М.Г., Бузунов Р.В., Авербух В.М. и др. Проект клинических рекомендаций по диагностике и лечению хронической инсомнии у взрослых. Consilium Medicum. Неврология и Ревматология (Прил.). 2016; 2: 41–51.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Инсомния представляет собой широко распространенное в общей популяции состояние, которое сопряжено с многочисленными социальными и медицинскими последствиями. Представлены первые отечественные клинические рекомендации профессионального сообщества по диагностике и лечению хронической инсомнии, основанные на современной классификации расстройств сна и результатах рандомизированных клинических исследований.
Ключевые слова: сон, инсомния, клинические рекомендации, снотворные, когнитивно-поведенческая терапия.
Key words: sleep, insomnia, clinical recommendations, hypnotics, cognitive-behavioral therapy.
Ключевые слова: сон, инсомния, клинические рекомендации, снотворные, когнитивно-поведенческая терапия.
________________________________________________
Key words: sleep, insomnia, clinical recommendations, hypnotics, cognitive-behavioral therapy.
Полный текст
Список литературы
1. The International classification of sleep disorders (Diagnostic and coding manual). American Academy of Sleep Medicine. U.S.A.: Darien, 2014.
2. Lichstein KL, Taylor DJ, McCrae CS, Petrov ME. Insomnia: epidemiology and risk factors. In: Kryger MH, Roth T, Dement WC (eds.) Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 761–8.
3. Botteman MF, Ozminkowski RJ, Wang S et al. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model. CNS Drugs 2007; 21 (4): 319–34.
4. Anderson LH, Whitebird RR, Schultz J et al. Healthcare utilization and costs in persons with insomnia in a managed care population. Am J Manag Care 2014; 20 (5):157–65.
5. Léger D, Massuel MA, Metlaine A. Professional correlates of insomnia. Sleep 2006; 29 (2): 171–8.
6. Международная статистическая классификация болезней и проблем, связанных со здоровьем, десятый пересмотр (МКБ-Х). Том 1. М.: Медицина, 1989. / Mezhdunarodnaia statisticheskaia klassifikatsiia boleznei i problem, sviazannykh so zdorov'em, desiatyi peresmotr (MKB-Kh). Tom 1. M.: Meditsina, 1989. [in Russian]
7. NIH State-of-the-Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults. NIH Consens Sci Statements 2005; 22 (2): 1–30.
8. Schutte-Rodin S, Broch L, Buysse D et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008; 4 (5): 487–504.
9. Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 2010; 24 (11): 1577–601.
10. Meschia JF, Bushnell C, Boden-Albala B et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45 (12): 3754–832.
11. Голенков А.В., Полуэктов М.Г. Распространенность нарушений сна у жителей Чувашии (данные сплошного анкетного опроса). Журн. неврологии и психиатрии им. С.С.Корсакова. 2011; 111 (6): 64–7. / Golenkov A.V., Poluektov M.G. Rasprostranennost' narushenii sna u zhitelei Chuvashii (dannye sploshnogo anketnogo oprosa). Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2011; 111 (6): 64–7. [in Russian]
12. Гафаров В.В., Пак В.А., Гагулин И.В., Гафарова А.В. Психология здоровья населения в России. Новосибирск: СО РАМН, 2002; с. 359. / Gafarov V.V., Pak V.A., Gagulin I.V., Gafarova A.V. Psikhologiia zdorov'ia naseleniia v Rossii. Novosibirsk: SO RAMN, 2002; s. 359. [in Russian]
13. Голенков А.В., Полуэктов М.Г. Особенности и нарушения сна в пожилом и старческом возрасте. Клиническая геронтология. 2012; 7–8: 8–13. / Golenkov A.V., Poluektov M.G. Osobennosti i narusheniia sna v pozhilom i starcheskom vozraste. Klinicheskaia gerontologiia. 2012; 7–8: 8–13. [in Russian]
14. Brower KJ, McCammon RJ, Wojnar M et al. Prescription sleeping pills, insomnia, and suicidality in the National Comorbidity Survey Replication. J Clin Psychiatry 2011; 72 (4): 515–21.
15. Полуэктов М.Г. Клинический алгоритм диагностического и лечебного выбора при инсомнии. Эффективная фармакотерапия. 2013; 12: 22–8. / Poluektov M.G. Klinicheskii algoritm diagnosticheskogo i lechebnogo vybora pri insomnii. Effektivnaia farmakoterapiia. 2013; 12: 22–8. [in Russian]
16. Ong JC, Arnedt JT, Gehrman PR. Insomnia diagnosis, assessment and evaluation. In: Kryger MH, Roth T, Dement WC (eds.) Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 785–93.
17. Полуэктов МГ. Инсомнии. В кн.: Сомнология и медицина сна. Национальное руководство памяти А.М.Вейна и Я.И.Левина. Под ред. М.Г.Полуэктова. М.: Медфорум, 2016; с. 298–318. / Poluektov MG. Insomnii. V kn.: Somnologiia i meditsina sna. Natsional'noe rukovodstvo pamiati A.M.Veina i Ia.I.Levina. Pod red. M.G.Poluektova. M.: Medforum, 2016; s. 298–318. [in Russian]
18. Morgenthaler T, Alessi C, Friedman L et al. Practice parameters for the use of actigraphy in the assessment of sleep and sleep disorders: an update for 2007. Sleep 2007; 30 (4): 519–29.
19. Магомедова К.А., Полуэктов М.Г. Применение актиграфии для выявления нарушений сна у лиц старших возрастных групп. Клиническая геронтология. 2014; 20 (3–4): 35–8. / Magomedova K.A., Poluektov M.G. Primenenie aktigrafii dlia vyiavleniia narushenii sna u lits starshikh vozrastnykh grupp. Klinicheskaia gerontologiia. 2014; 20 (3–4): 35–8. [in Russian]
20. Kushida CA, Littner MR, Morgenthaler T et al. Practice parameters for the indications for polysomnography and related procedures: an update for 2005. Sleep 2005; 28 (4): 499–521.
21. Buysse DJ, Reynolds CF, Monk TH et al. The Pittsburgh Sleep Quality Index (PSQI): a new instrument for psychiatric research and practice. Psychiatry Res 1989; 28: 193–213.
22. Morin CM. Insomnia: Psychological assessment and management. New York: Guilford Press, 1993.
23. Espie CA, Inglis SJ, Harvey L, Tessier S. Insomniacs' attributions. psychometric properties of the Dysfunctional Beliefs and Attitudes about Sleep Scale and the Sleep Disturbance Questionnaire. J Psychosom Res 2000; 48 (2): 141–8.
24. Левин Я.И., Елигулашвили Т.С., Посохов С.И. и др. Фармакотерапия инсомний: роль Имована. В кн.: Расстройства сна. Под ред. Ю.А.Александровского, А.М.Вейна. СПб: Мед. информ. агентство, 1995; с. 56–61. / Levin Ia.I., Eligulashvili T.S., Posokhov S.I. i dr. Farmakoterapiia insomnii: rol' Imovana. V kn.: Rasstroistva sna. Pod red. Iu.A.Aleksandrovskogo, A.M.Veina. SPb: Med. inform. agentstvo, 1995; s. 56–61. [in Russian]
25. Spielman A, Caruso L, Glovinsky P. A behavioral perspective on insomnia treatment. Psychiatric Clinic of North America 1987; 10: 541–53.
26. Perlis ML, Ellis JG, Kloss JD, Riemann DW. Etiology and Pathophysiology of Insomnia. In: Kryger MH, Roth T, Dement WC (eds.) Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 769–84.
27. Morin CM, Davidson JR, Beaulieu-Bonneau S. Cognitive Behavior Therapies for Insomnia I: Approaches and Efficacy. In: Kryger MH, Roth T, Dement WC (eds.). Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 804–13.
28. Zachariae R, Lyby MS, Ritterband LM, O'Toole MS. Efficacy of internet-delivered cognitive-behavioral therapy for insomnia: A systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev 2015; 30: 1–10.
29. Trauer JM, Qian MY, Doyle JS et al. Cognitive Behavioral Therapy for Chronic Insomnia: A systematic review and meta-analysis. Ann Intern Med 2015; 163 (3): 191–204.
30. Carson S, McDonagh MS, Thakurta S, Yen PY. Drug Class Review: Newer Drugs for Insomnia: Final Report Update 2 [Internet]. Portland (OR): Oregon Health & Science University. 2008.
31. Левин Я.И. Клинический опыт применения зопиклона (Релаксон) при инсомнии. Эффективная фармакотерапия. 2011; 1: 14–20. / Levin Ia.I. Klinicheskii opyt primeneniia zopiklona (Relakson) pri insomnii. Effektivnaia farmakoterapiia. 2011; 1: 14–20. [in Russian]
32. Стрыгин К.Н., Левин Я.И. Современная терапия инсомнии: роль зопиклона. Неврология и ревматология. 2010; 1: 48–52. / Strygin K.N., Levin Ia.I. Sovremennaia terapiia insomnii: rol' zopiklona. Nevrologiia i revmatologiia. 2010; 1: 48–52. [in Russian]
33. MacFarlane J, Morin CM, Montplaisir J. Hypnotics in insomnia: the experience of zolpidem. Clin Ther 2014; 36 (11): 1676–701.
34. Шмыров В.И., Клочкова Л.Б. Открытое многоцентровое исследование золпидема (Ивадала) при лечении инсомнии. Фарматека. 2001; 5: 32–43. / Shmyrov V.I., Klochkova L.B. Otkrytoe mnogotsentrovoe issledovanie zolpidema (Ivadala) pri lechenii insomnii. Farmateka. 2001; 5: 32–43. [in Russian]
35. Левин Я.И. Инсомния: клинический опыт применения золпидема (Санвал). Неврол. нейропсихиатр. психосом. 2010; 3: 87–91. / Levin Ia.I. Insomniia: klinicheskii opyt primeneniia zolpidema (Sanval). Nevrol. neiropsikhiatr. psikhosom. 2010; 3: 87–91. [in Russian]
36. Ancoli-Israel S, Richardson GS, Mangano RM et al. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med 2005; 6: 107–13.
37. Kales A, Manfredi RL, Vgontzas AN et al. Clonazepam: sleep laboratory study of efficacy and withdrawal. J Clin Psychopharmacol 1991; 11 (3): 189–93.
38. Dashti-Khavidaki S, Chamani N, Khalili H. Comparing effects of clonazepam and zolpidem on sleep quality of patients on maintenance hemodialysis. Iran J Kidney Dis 2011; 5 (6): 404–9.
39. Kok LP, Tsoi WF. Comparison of midazolam, diazepam and placebo in the treatment of insomnia. Singapore Med J 1986; 27 (3): 200–3.
40. Walsh JK, Roth T. Pharmacologic Treatment of Insomnia: Benzodiazepine Receptor Agonists. In: Kryger MH, Roth T, Dement WC (eds.) Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 832–41.
41. Montplaisir J, Hawa R, Moller H et al. Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement. Hum Psychopharmacol 2003; 18 (1): 29–38.
42. Wyatt JK, Dijk DJ, Ritz-de Cecco A et al. Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep 2006; 29 (5): 609–18.
43. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One 2013; 8 (5): e63773.
44. Costello RB, Lentino CV, Boyd CC et al. The effectiveness of melatonin for promoting healthy sleep: a rapid evidence assessment of the literature. Nutr J 2014; 13:106.
45. Полуэктов М.Г., Левин Я.И., Бойко А.Н. и др. Результаты российского мультицентрового исследования эффективности и безопасности мелаксена (мелатонин) для лечения нарушений сна у пациентов с хронической церебральной сосудистой недостаточностью. Журн. неврологии и психиатрии им. C.C.Корсакова. 2012; 112 (9): 26–31. / Poluektov M.G., Levin Ia.I., Boiko A.N. i dr. Rezul'taty rossiiskogo mul'titsentrovogo issledovaniia effektivnosti i bezopasnosti melaksena (melatonin) dlia lecheniia narushenii sna u patsientov s khronicheskoi tserebral'noi sosudistoi nedostatochnost'iu. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2012; 112 (9): 26–31. [in Russian]
46. Ковров Г.В., Агальцов М.В., Сукмарова З.Н. Эффективность мелатонина пролонгированного высвобождения при первичных нарушениях сна у пациентов старше 55 лет. Неврология, нейропсихиатрия, психосоматика. 2016; 8 (2): 24–30. / Kovrov G.V., Agal'tsov M.V., Sukmarova Z.N. Effektivnost' melatonina prolongirovannogo vysvobozhdeniia pri pervichnykh narusheniiakh sna u patsientov starshe 55 let. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2016; 8 (2): 24–30. [in Russian]
47. Литвиненко И.В., Красаков И.В., Тихомирова О.В. Расстройства сна при неосложненной деменцией болезни Паркинсона: результаты контролируемого сравнительного исследования применения мелатонина и клоназепама. Журн. неврологии и психиатрии им. C.C.Корсакова. 2012; 112 (12): 26–30. / Litvinenko I.V., Krasakov I.V., Tikhomirova O.V. Rasstroistva sna pri neoslozhnennoi dementsiei bolezni Parkinsona: rezul'taty kontroliruemogo sravnitel'nogo issledovaniia primeneniia melatonina i klonazepama. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2012; 112 (12): 26–30. [in Russian]
48. Федорова Н.В., Никитина А.В., Губанова Е.В. Роль мелатонина в терапии первичных нарушений сна у пациентов с болезнью Паркинсона. Consilium Medicum. Неврология и Ревматология (Прил.). 2012; 2: 69–72. / Fedorova N.V., Nikitina A.V., Gubanova E.V. Rol' melatonina v terapii pervichnykh narushenii sna u patsientov s bolezn'iu Parkinsona. Consilium Medicum. Neurology and Rheumatology (Suppl.). 2012; 2: 69–72. / [in Russian]
49. Glass JR, Sproule BA, Herrmann N, Busto UE. Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trial. J Clin Psychopharmacol 2008; 28 (2): 182–8.
50. Morin CM, Koetter U, Bastien C et al. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep 2005; 28 (11): 1465–71.
51. Smith GM, Smith PH. Effects of doxylamine and acetaminophen on postoperative sleep. Clin Pharmacol Ther 1985; 37 (5): 549–57.
52. Schadeck B, Chelly M, Amsellem D. et al. Comparative efficacy of doxylamine (15 mg ) and zolpidem (10 mg) for the treatment of common insomnia – a placebo-controlled study. La Semaine des hopitaux de Paris 1993; 72 (13–14): 428–39.
53. Мадаева И.М., Шевырталова О.Н., Мадаев В.В. Применение доксиламина при инсомнии у пациентов с артериальной гипертензией. Сonsilium Medicum. 2009; 11 (9): 69–72. / Madaeva I.M., Shevyrtalova O.N., Madaev V.V. Primenenie doksilamina pri insomnii u patsientov s arterial'noi gipertenziei. Sonsilium Medicum. 2009; 11 (9): 69–72. [in Russian]
54. Vande Griend JP, Anderson SL. Histamine-1 receptor antagonism for treatment of insomnia. J Am Pharm Assoc (2003) 2012; 52 (6): e210–9.
55. Krystal AD. Pharmacologic treatment of insomnia: other medications. In: Kryger MH, Roth T., Dement W.C. (eds.) Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 842–54.
56. Tassniyom K, Paholpak S, Tassniyom S, Kiewyoo J. Quetiapine for primary insomnia: a double blind, randomized controlled trial. J Med Assoc Thai 2010; 93 (6): 729–34.
57. Brower KJ, Myra Kim H, Strobbe S et al. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res 2008; 32 (8): 1429–38.
58. Fernández-San-Martín MI, Masa-Font R, Palacios-Soler L et al. Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med 2010; 11 (6): 505–11.
59. Douros A, Bronder E, Andersohn F et al. Herb-induced liver injury in the Berlin case-control surveillance study. Int J Mol Sci 2016; 17 (1): pii: E114.
60. Kolla BP, Lovely JK, Mansukhani MP, Morgenthaler TI. Zolpidem is independently associated with increased risk of inpatient falls. J Hosp Med 2013; 8 (1): 1–6.
61. Madjunkova S, Maltepe C, Koren G. The delayed-release combination of doxylamine and pyridoxine (DiclegisR/DiclectinR) for the treatment of nausea and vomiting of pregnancy. Paediatr Drugs 2014; 16 (3): 199–211.
2. Lichstein KL, Taylor DJ, McCrae CS, Petrov ME. Insomnia: epidemiology and risk factors. In: Kryger MH, Roth T, Dement WC (eds.) Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 761–8.
3. Botteman MF, Ozminkowski RJ, Wang S et al. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model. CNS Drugs 2007; 21 (4): 319–34.
4. Anderson LH, Whitebird RR, Schultz J et al. Healthcare utilization and costs in persons with insomnia in a managed care population. Am J Manag Care 2014; 20 (5):157–65.
5. Léger D, Massuel MA, Metlaine A. Professional correlates of insomnia. Sleep 2006; 29 (2): 171–8.
6. Mezhdunarodnaia statisticheskaia klassifikatsiia boleznei i problem, sviazannykh so zdorov'em, desiatyi peresmotr (MKB-Kh). Tom 1. M.: Meditsina, 1989. [in Russian]
7. NIH State-of-the-Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults. NIH Consens Sci Statements 2005; 22 (2): 1–30.
8. Schutte-Rodin S, Broch L, Buysse D et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008; 4 (5): 487–504.
9. Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 2010; 24 (11): 1577–601.
10. Meschia JF, Bushnell C, Boden-Albala B et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45 (12): 3754–832.
11. Golenkov A.V., Poluektov M.G. Rasprostranennost' narushenii sna u zhitelei Chuvashii (dannye sploshnogo anketnogo oprosa). Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2011; 111 (6): 64–7. [in Russian]
12. Gafarov V.V., Pak V.A., Gagulin I.V., Gafarova A.V. Psikhologiia zdorov'ia naseleniia v Rossii. Novosibirsk: SO RAMN, 2002; s. 359. [in Russian]
13. Golenkov A.V., Poluektov M.G. Osobennosti i narusheniia sna v pozhilom i starcheskom vozraste. Klinicheskaia gerontologiia. 2012; 7–8: 8–13. [in Russian]
14. Brower KJ, McCammon RJ, Wojnar M et al. Prescription sleeping pills, insomnia, and suicidality in the National Comorbidity Survey Replication. J Clin Psychiatry 2011; 72 (4): 515–21.
15. Poluektov M.G. Klinicheskii algoritm diagnosticheskogo i lechebnogo vybora pri insomnii. Effektivnaia farmakoterapiia. 2013; 12: 22–8. [in Russian]
16. Ong JC, Arnedt JT, Gehrman PR. Insomnia diagnosis, assessment and evaluation. In: Kryger MH, Roth T, Dement WC (eds.) Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 785–93.
17. Poluektov MG. Insomnii. V kn.: Somnologiia i meditsina sna. Natsional'noe rukovodstvo pamiati A.M.Veina i Ia.I.Levina. Pod red. M.G.Poluektova. M.: Medforum, 2016; s. 298–318. [in Russian]
18. Morgenthaler T, Alessi C, Friedman L et al. Practice parameters for the use of actigraphy in the assessment of sleep and sleep disorders: an update for 2007. Sleep 2007; 30 (4): 519–29.
19. Magomedova K.A., Poluektov M.G. Primenenie aktigrafii dlia vyiavleniia narushenii sna u lits starshikh vozrastnykh grupp. Klinicheskaia gerontologiia. 2014; 20 (3–4): 35–8. [in Russian]
20. Kushida CA, Littner MR, Morgenthaler T et al. Practice parameters for the indications for polysomnography and related procedures: an update for 2005. Sleep 2005; 28 (4): 499–521.
21. Buysse DJ, Reynolds CF, Monk TH et al. The Pittsburgh Sleep Quality Index (PSQI): a new instrument for psychiatric research and practice. Psychiatry Res 1989; 28: 193–213.
22. Morin CM. Insomnia: Psychological assessment and management. New York: Guilford Press, 1993.
23. Espie CA, Inglis SJ, Harvey L, Tessier S. Insomniacs' attributions. psychometric properties of the Dysfunctional Beliefs and Attitudes about Sleep Scale and the Sleep Disturbance Questionnaire. J Psychosom Res 2000; 48 (2): 141–8.
24. Levin Ia.I., Eligulashvili T.S., Posokhov S.I. i dr. Farmakoterapiia insomnii: rol' Imovana. V kn.: Rasstroistva sna. Pod red. Iu.A.Aleksandrovskogo, A.M.Veina. SPb: Med. inform. agentstvo, 1995; s. 56–61. [in Russian]
25. Spielman A, Caruso L, Glovinsky P. A behavioral perspective on insomnia treatment. Psychiatric Clinic of North America 1987; 10: 541–53.
26. Perlis ML, Ellis JG, Kloss JD, Riemann DW. Etiology and Pathophysiology of Insomnia. In: Kryger MH, Roth T, Dement WC (eds.) Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 769–84.
27. Morin CM, Davidson JR, Beaulieu-Bonneau S. Cognitive Behavior Therapies for Insomnia I: Approaches and Efficacy. In: Kryger MH, Roth T, Dement WC (eds.). Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 804–13.
28. Zachariae R, Lyby MS, Ritterband LM, O'Toole MS. Efficacy of internet-delivered cognitive-behavioral therapy for insomnia: A systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev 2015; 30: 1–10.
29. Trauer JM, Qian MY, Doyle JS et al. Cognitive Behavioral Therapy for Chronic Insomnia: A systematic review and meta-analysis. Ann Intern Med 2015; 163 (3): 191–204.
30. Carson S, McDonagh MS, Thakurta S, Yen PY. Drug Class Review: Newer Drugs for Insomnia: Final Report Update 2 [Internet]. Portland (OR): Oregon Health & Science University. 2008.
31. Levin Ia.I. Klinicheskii opyt primeneniia zopiklona (Relakson) pri insomnii. Effektivnaia farmakoterapiia. 2011; 1: 14–20. [in Russian]
32. Strygin K.N., Levin Ia.I. Sovremennaia terapiia insomnii: rol' zopiklona. Nevrologiia i revmatologiia. 2010; 1: 48–52. [in Russian]
33. MacFarlane J, Morin CM, Montplaisir J. Hypnotics in insomnia: the experience of zolpidem. Clin Ther 2014; 36 (11): 1676–701.
34. Shmyrov V.I., Klochkova L.B. Otkrytoe mnogotsentrovoe issledovanie zolpidema (Ivadala) pri lechenii insomnii. Farmateka. 2001; 5: 32–43. [in Russian]
35. Levin Ia.I. Insomniia: klinicheskii opyt primeneniia zolpidema (Sanval). Nevrol. neiropsikhiatr. psikhosom. 2010; 3: 87–91. [in Russian]
36. Ancoli-Israel S, Richardson GS, Mangano RM et al. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med 2005; 6: 107–13.
37. Kales A, Manfredi RL, Vgontzas AN et al. Clonazepam: sleep laboratory study of efficacy and withdrawal. J Clin Psychopharmacol 1991; 11 (3): 189–93.
38. Dashti-Khavidaki S, Chamani N, Khalili H. Comparing effects of clonazepam and zolpidem on sleep quality of patients on maintenance hemodialysis. Iran J Kidney Dis 2011; 5 (6): 404–9.
39. Kok LP, Tsoi WF. Comparison of midazolam, diazepam and placebo in the treatment of insomnia. Singapore Med J 1986; 27 (3): 200–3.
40. Walsh JK, Roth T. Pharmacologic Treatment of Insomnia: Benzodiazepine Receptor Agonists. In: Kryger MH, Roth T, Dement WC (eds.) Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 832–41.
41. Montplaisir J, Hawa R, Moller H et al. Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement. Hum Psychopharmacol 2003; 18 (1): 29–38.
42. Wyatt JK, Dijk DJ, Ritz-de Cecco A et al. Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep 2006; 29 (5): 609–18.
43. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One 2013; 8 (5): e63773.
44. Costello RB, Lentino CV, Boyd CC et al. The effectiveness of melatonin for promoting healthy sleep: a rapid evidence assessment of the literature. Nutr J 2014; 13:106.
45. Poluektov M.G., Levin Ia.I., Boiko A.N. i dr. Rezul'taty rossiiskogo mul'titsentrovogo issledovaniia effektivnosti i bezopasnosti melaksena (melatonin) dlia lecheniia narushenii sna u patsientov s khronicheskoi tserebral'noi sosudistoi nedostatochnost'iu. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2012; 112 (9): 26–31. [in Russian]
46. Kovrov G.V., Agal'tsov M.V., Sukmarova Z.N. Effektivnost' melatonina prolongirovannogo vysvobozhdeniia pri pervichnykh narusheniiakh sna u patsientov starshe 55 let. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2016; 8 (2): 24–30. [in Russian]
47. Litvinenko I.V., Krasakov I.V., Tikhomirova O.V. Rasstroistva sna pri neoslozhnennoi dementsiei bolezni Parkinsona: rezul'taty kontroliruemogo sravnitel'nogo issledovaniia primeneniia melatonina i klonazepama. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2012; 112 (12): 26–30. [in Russian]
48. Fedorova N.V., Nikitina A.V., Gubanova E.V. Rol' melatonina v terapii pervichnykh narushenii sna u patsientov s bolezn'iu Parkinsona. Consilium Medicum. Neurology and Rheumatology (Suppl.). 2012; 2: 69–72. / [in Russian]
49. Glass JR, Sproule BA, Herrmann N, Busto UE. Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trial. J Clin Psychopharmacol 2008; 28 (2): 182–8.
50. Morin CM, Koetter U, Bastien C et al. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep 2005; 28 (11): 1465–71.
51. Smith GM, Smith PH. Effects of doxylamine and acetaminophen on postoperative sleep. Clin Pharmacol Ther 1985; 37 (5): 549–57.
52. Schadeck B, Chelly M, Amsellem D. et al. Comparative efficacy of doxylamine (15 mg ) and zolpidem (10 mg) for the treatment of common insomnia – a placebo-controlled study. La Semaine des hopitaux de Paris 1993; 72 (13–14): 428–39.
53. Madaeva I.M., Shevyrtalova O.N., Madaev V.V. Primenenie doksilamina pri insomnii u patsientov s arterial'noi gipertenziei. Sonsilium Medicum. 2009; 11 (9): 69–72. [in Russian]
54. Vande Griend JP, Anderson SL. Histamine-1 receptor antagonism for treatment of insomnia. J Am Pharm Assoc (2003) 2012; 52 (6): e210–9.
55. Krystal AD. Pharmacologic treatment of insomnia: other medications. In: Kryger MH, Roth T., Dement W.C. (eds.) Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 842–54.
56. Tassniyom K, Paholpak S, Tassniyom S, Kiewyoo J. Quetiapine for primary insomnia: a double blind, randomized controlled trial. J Med Assoc Thai 2010; 93 (6): 729–34.
57. Brower KJ, Myra Kim H, Strobbe S et al. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res 2008; 32 (8): 1429–38.
58. Fernández-San-Martín MI, Masa-Font R, Palacios-Soler L et al. Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med 2010; 11 (6): 505–11.
59. Douros A, Bronder E, Andersohn F et al. Herb-induced liver injury in the Berlin case-control surveillance study. Int J Mol Sci 2016; 17 (1): pii: E114.
60. Kolla BP, Lovely JK, Mansukhani MP, Morgenthaler TI. Zolpidem is independently associated with increased risk of inpatient falls. J Hosp Med 2013; 8 (1): 1–6.
61. Madjunkova S, Maltepe C, Koren G. The delayed-release combination of doxylamine and pyridoxine (DiclegisR/DiclectinR) for the treatment of nausea and vomiting of pregnancy. Paediatr Drugs 2014; 16 (3): 199–211.
2. Lichstein KL, Taylor DJ, McCrae CS, Petrov ME. Insomnia: epidemiology and risk factors. In: Kryger MH, Roth T, Dement WC (eds.) Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 761–8.
3. Botteman MF, Ozminkowski RJ, Wang S et al. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model. CNS Drugs 2007; 21 (4): 319–34.
4. Anderson LH, Whitebird RR, Schultz J et al. Healthcare utilization and costs in persons with insomnia in a managed care population. Am J Manag Care 2014; 20 (5):157–65.
5. Léger D, Massuel MA, Metlaine A. Professional correlates of insomnia. Sleep 2006; 29 (2): 171–8.
6. Международная статистическая классификация болезней и проблем, связанных со здоровьем, десятый пересмотр (МКБ-Х). Том 1. М.: Медицина, 1989. / Mezhdunarodnaia statisticheskaia klassifikatsiia boleznei i problem, sviazannykh so zdorov'em, desiatyi peresmotr (MKB-Kh). Tom 1. M.: Meditsina, 1989. [in Russian]
7. NIH State-of-the-Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults. NIH Consens Sci Statements 2005; 22 (2): 1–30.
8. Schutte-Rodin S, Broch L, Buysse D et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008; 4 (5): 487–504.
9. Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 2010; 24 (11): 1577–601.
10. Meschia JF, Bushnell C, Boden-Albala B et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45 (12): 3754–832.
11. Голенков А.В., Полуэктов М.Г. Распространенность нарушений сна у жителей Чувашии (данные сплошного анкетного опроса). Журн. неврологии и психиатрии им. С.С.Корсакова. 2011; 111 (6): 64–7. / Golenkov A.V., Poluektov M.G. Rasprostranennost' narushenii sna u zhitelei Chuvashii (dannye sploshnogo anketnogo oprosa). Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2011; 111 (6): 64–7. [in Russian]
12. Гафаров В.В., Пак В.А., Гагулин И.В., Гафарова А.В. Психология здоровья населения в России. Новосибирск: СО РАМН, 2002; с. 359. / Gafarov V.V., Pak V.A., Gagulin I.V., Gafarova A.V. Psikhologiia zdorov'ia naseleniia v Rossii. Novosibirsk: SO RAMN, 2002; s. 359. [in Russian]
13. Голенков А.В., Полуэктов М.Г. Особенности и нарушения сна в пожилом и старческом возрасте. Клиническая геронтология. 2012; 7–8: 8–13. / Golenkov A.V., Poluektov M.G. Osobennosti i narusheniia sna v pozhilom i starcheskom vozraste. Klinicheskaia gerontologiia. 2012; 7–8: 8–13. [in Russian]
14. Brower KJ, McCammon RJ, Wojnar M et al. Prescription sleeping pills, insomnia, and suicidality in the National Comorbidity Survey Replication. J Clin Psychiatry 2011; 72 (4): 515–21.
15. Полуэктов М.Г. Клинический алгоритм диагностического и лечебного выбора при инсомнии. Эффективная фармакотерапия. 2013; 12: 22–8. / Poluektov M.G. Klinicheskii algoritm diagnosticheskogo i lechebnogo vybora pri insomnii. Effektivnaia farmakoterapiia. 2013; 12: 22–8. [in Russian]
16. Ong JC, Arnedt JT, Gehrman PR. Insomnia diagnosis, assessment and evaluation. In: Kryger MH, Roth T, Dement WC (eds.) Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 785–93.
17. Полуэктов МГ. Инсомнии. В кн.: Сомнология и медицина сна. Национальное руководство памяти А.М.Вейна и Я.И.Левина. Под ред. М.Г.Полуэктова. М.: Медфорум, 2016; с. 298–318. / Poluektov MG. Insomnii. V kn.: Somnologiia i meditsina sna. Natsional'noe rukovodstvo pamiati A.M.Veina i Ia.I.Levina. Pod red. M.G.Poluektova. M.: Medforum, 2016; s. 298–318. [in Russian]
18. Morgenthaler T, Alessi C, Friedman L et al. Practice parameters for the use of actigraphy in the assessment of sleep and sleep disorders: an update for 2007. Sleep 2007; 30 (4): 519–29.
19. Магомедова К.А., Полуэктов М.Г. Применение актиграфии для выявления нарушений сна у лиц старших возрастных групп. Клиническая геронтология. 2014; 20 (3–4): 35–8. / Magomedova K.A., Poluektov M.G. Primenenie aktigrafii dlia vyiavleniia narushenii sna u lits starshikh vozrastnykh grupp. Klinicheskaia gerontologiia. 2014; 20 (3–4): 35–8. [in Russian]
20. Kushida CA, Littner MR, Morgenthaler T et al. Practice parameters for the indications for polysomnography and related procedures: an update for 2005. Sleep 2005; 28 (4): 499–521.
21. Buysse DJ, Reynolds CF, Monk TH et al. The Pittsburgh Sleep Quality Index (PSQI): a new instrument for psychiatric research and practice. Psychiatry Res 1989; 28: 193–213.
22. Morin CM. Insomnia: Psychological assessment and management. New York: Guilford Press, 1993.
23. Espie CA, Inglis SJ, Harvey L, Tessier S. Insomniacs' attributions. psychometric properties of the Dysfunctional Beliefs and Attitudes about Sleep Scale and the Sleep Disturbance Questionnaire. J Psychosom Res 2000; 48 (2): 141–8.
24. Левин Я.И., Елигулашвили Т.С., Посохов С.И. и др. Фармакотерапия инсомний: роль Имована. В кн.: Расстройства сна. Под ред. Ю.А.Александровского, А.М.Вейна. СПб: Мед. информ. агентство, 1995; с. 56–61. / Levin Ia.I., Eligulashvili T.S., Posokhov S.I. i dr. Farmakoterapiia insomnii: rol' Imovana. V kn.: Rasstroistva sna. Pod red. Iu.A.Aleksandrovskogo, A.M.Veina. SPb: Med. inform. agentstvo, 1995; s. 56–61. [in Russian]
25. Spielman A, Caruso L, Glovinsky P. A behavioral perspective on insomnia treatment. Psychiatric Clinic of North America 1987; 10: 541–53.
26. Perlis ML, Ellis JG, Kloss JD, Riemann DW. Etiology and Pathophysiology of Insomnia. In: Kryger MH, Roth T, Dement WC (eds.) Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 769–84.
27. Morin CM, Davidson JR, Beaulieu-Bonneau S. Cognitive Behavior Therapies for Insomnia I: Approaches and Efficacy. In: Kryger MH, Roth T, Dement WC (eds.). Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 804–13.
28. Zachariae R, Lyby MS, Ritterband LM, O'Toole MS. Efficacy of internet-delivered cognitive-behavioral therapy for insomnia: A systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev 2015; 30: 1–10.
29. Trauer JM, Qian MY, Doyle JS et al. Cognitive Behavioral Therapy for Chronic Insomnia: A systematic review and meta-analysis. Ann Intern Med 2015; 163 (3): 191–204.
30. Carson S, McDonagh MS, Thakurta S, Yen PY. Drug Class Review: Newer Drugs for Insomnia: Final Report Update 2 [Internet]. Portland (OR): Oregon Health & Science University. 2008.
31. Левин Я.И. Клинический опыт применения зопиклона (Релаксон) при инсомнии. Эффективная фармакотерапия. 2011; 1: 14–20. / Levin Ia.I. Klinicheskii opyt primeneniia zopiklona (Relakson) pri insomnii. Effektivnaia farmakoterapiia. 2011; 1: 14–20. [in Russian]
32. Стрыгин К.Н., Левин Я.И. Современная терапия инсомнии: роль зопиклона. Неврология и ревматология. 2010; 1: 48–52. / Strygin K.N., Levin Ia.I. Sovremennaia terapiia insomnii: rol' zopiklona. Nevrologiia i revmatologiia. 2010; 1: 48–52. [in Russian]
33. MacFarlane J, Morin CM, Montplaisir J. Hypnotics in insomnia: the experience of zolpidem. Clin Ther 2014; 36 (11): 1676–701.
34. Шмыров В.И., Клочкова Л.Б. Открытое многоцентровое исследование золпидема (Ивадала) при лечении инсомнии. Фарматека. 2001; 5: 32–43. / Shmyrov V.I., Klochkova L.B. Otkrytoe mnogotsentrovoe issledovanie zolpidema (Ivadala) pri lechenii insomnii. Farmateka. 2001; 5: 32–43. [in Russian]
35. Левин Я.И. Инсомния: клинический опыт применения золпидема (Санвал). Неврол. нейропсихиатр. психосом. 2010; 3: 87–91. / Levin Ia.I. Insomniia: klinicheskii opyt primeneniia zolpidema (Sanval). Nevrol. neiropsikhiatr. psikhosom. 2010; 3: 87–91. [in Russian]
36. Ancoli-Israel S, Richardson GS, Mangano RM et al. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med 2005; 6: 107–13.
37. Kales A, Manfredi RL, Vgontzas AN et al. Clonazepam: sleep laboratory study of efficacy and withdrawal. J Clin Psychopharmacol 1991; 11 (3): 189–93.
38. Dashti-Khavidaki S, Chamani N, Khalili H. Comparing effects of clonazepam and zolpidem on sleep quality of patients on maintenance hemodialysis. Iran J Kidney Dis 2011; 5 (6): 404–9.
39. Kok LP, Tsoi WF. Comparison of midazolam, diazepam and placebo in the treatment of insomnia. Singapore Med J 1986; 27 (3): 200–3.
40. Walsh JK, Roth T. Pharmacologic Treatment of Insomnia: Benzodiazepine Receptor Agonists. In: Kryger MH, Roth T, Dement WC (eds.) Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 832–41.
41. Montplaisir J, Hawa R, Moller H et al. Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement. Hum Psychopharmacol 2003; 18 (1): 29–38.
42. Wyatt JK, Dijk DJ, Ritz-de Cecco A et al. Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep 2006; 29 (5): 609–18.
43. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One 2013; 8 (5): e63773.
44. Costello RB, Lentino CV, Boyd CC et al. The effectiveness of melatonin for promoting healthy sleep: a rapid evidence assessment of the literature. Nutr J 2014; 13:106.
45. Полуэктов М.Г., Левин Я.И., Бойко А.Н. и др. Результаты российского мультицентрового исследования эффективности и безопасности мелаксена (мелатонин) для лечения нарушений сна у пациентов с хронической церебральной сосудистой недостаточностью. Журн. неврологии и психиатрии им. C.C.Корсакова. 2012; 112 (9): 26–31. / Poluektov M.G., Levin Ia.I., Boiko A.N. i dr. Rezul'taty rossiiskogo mul'titsentrovogo issledovaniia effektivnosti i bezopasnosti melaksena (melatonin) dlia lecheniia narushenii sna u patsientov s khronicheskoi tserebral'noi sosudistoi nedostatochnost'iu. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2012; 112 (9): 26–31. [in Russian]
46. Ковров Г.В., Агальцов М.В., Сукмарова З.Н. Эффективность мелатонина пролонгированного высвобождения при первичных нарушениях сна у пациентов старше 55 лет. Неврология, нейропсихиатрия, психосоматика. 2016; 8 (2): 24–30. / Kovrov G.V., Agal'tsov M.V., Sukmarova Z.N. Effektivnost' melatonina prolongirovannogo vysvobozhdeniia pri pervichnykh narusheniiakh sna u patsientov starshe 55 let. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2016; 8 (2): 24–30. [in Russian]
47. Литвиненко И.В., Красаков И.В., Тихомирова О.В. Расстройства сна при неосложненной деменцией болезни Паркинсона: результаты контролируемого сравнительного исследования применения мелатонина и клоназепама. Журн. неврологии и психиатрии им. C.C.Корсакова. 2012; 112 (12): 26–30. / Litvinenko I.V., Krasakov I.V., Tikhomirova O.V. Rasstroistva sna pri neoslozhnennoi dementsiei bolezni Parkinsona: rezul'taty kontroliruemogo sravnitel'nogo issledovaniia primeneniia melatonina i klonazepama. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2012; 112 (12): 26–30. [in Russian]
48. Федорова Н.В., Никитина А.В., Губанова Е.В. Роль мелатонина в терапии первичных нарушений сна у пациентов с болезнью Паркинсона. Consilium Medicum. Неврология и Ревматология (Прил.). 2012; 2: 69–72. / Fedorova N.V., Nikitina A.V., Gubanova E.V. Rol' melatonina v terapii pervichnykh narushenii sna u patsientov s bolezn'iu Parkinsona. Consilium Medicum. Neurology and Rheumatology (Suppl.). 2012; 2: 69–72. / [in Russian]
49. Glass JR, Sproule BA, Herrmann N, Busto UE. Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trial. J Clin Psychopharmacol 2008; 28 (2): 182–8.
50. Morin CM, Koetter U, Bastien C et al. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep 2005; 28 (11): 1465–71.
51. Smith GM, Smith PH. Effects of doxylamine and acetaminophen on postoperative sleep. Clin Pharmacol Ther 1985; 37 (5): 549–57.
52. Schadeck B, Chelly M, Amsellem D. et al. Comparative efficacy of doxylamine (15 mg ) and zolpidem (10 mg) for the treatment of common insomnia – a placebo-controlled study. La Semaine des hopitaux de Paris 1993; 72 (13–14): 428–39.
53. Мадаева И.М., Шевырталова О.Н., Мадаев В.В. Применение доксиламина при инсомнии у пациентов с артериальной гипертензией. Сonsilium Medicum. 2009; 11 (9): 69–72. / Madaeva I.M., Shevyrtalova O.N., Madaev V.V. Primenenie doksilamina pri insomnii u patsientov s arterial'noi gipertenziei. Sonsilium Medicum. 2009; 11 (9): 69–72. [in Russian]
54. Vande Griend JP, Anderson SL. Histamine-1 receptor antagonism for treatment of insomnia. J Am Pharm Assoc (2003) 2012; 52 (6): e210–9.
55. Krystal AD. Pharmacologic treatment of insomnia: other medications. In: Kryger MH, Roth T., Dement W.C. (eds.) Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 842–54.
56. Tassniyom K, Paholpak S, Tassniyom S, Kiewyoo J. Quetiapine for primary insomnia: a double blind, randomized controlled trial. J Med Assoc Thai 2010; 93 (6): 729–34.
57. Brower KJ, Myra Kim H, Strobbe S et al. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res 2008; 32 (8): 1429–38.
58. Fernández-San-Martín MI, Masa-Font R, Palacios-Soler L et al. Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med 2010; 11 (6): 505–11.
59. Douros A, Bronder E, Andersohn F et al. Herb-induced liver injury in the Berlin case-control surveillance study. Int J Mol Sci 2016; 17 (1): pii: E114.
60. Kolla BP, Lovely JK, Mansukhani MP, Morgenthaler TI. Zolpidem is independently associated with increased risk of inpatient falls. J Hosp Med 2013; 8 (1): 1–6.
61. Madjunkova S, Maltepe C, Koren G. The delayed-release combination of doxylamine and pyridoxine (DiclegisR/DiclectinR) for the treatment of nausea and vomiting of pregnancy. Paediatr Drugs 2014; 16 (3): 199–211.
________________________________________________
2. Lichstein KL, Taylor DJ, McCrae CS, Petrov ME. Insomnia: epidemiology and risk factors. In: Kryger MH, Roth T, Dement WC (eds.) Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 761–8.
3. Botteman MF, Ozminkowski RJ, Wang S et al. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model. CNS Drugs 2007; 21 (4): 319–34.
4. Anderson LH, Whitebird RR, Schultz J et al. Healthcare utilization and costs in persons with insomnia in a managed care population. Am J Manag Care 2014; 20 (5):157–65.
5. Léger D, Massuel MA, Metlaine A. Professional correlates of insomnia. Sleep 2006; 29 (2): 171–8.
6. Mezhdunarodnaia statisticheskaia klassifikatsiia boleznei i problem, sviazannykh so zdorov'em, desiatyi peresmotr (MKB-Kh). Tom 1. M.: Meditsina, 1989. [in Russian]
7. NIH State-of-the-Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults. NIH Consens Sci Statements 2005; 22 (2): 1–30.
8. Schutte-Rodin S, Broch L, Buysse D et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008; 4 (5): 487–504.
9. Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 2010; 24 (11): 1577–601.
10. Meschia JF, Bushnell C, Boden-Albala B et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45 (12): 3754–832.
11. Golenkov A.V., Poluektov M.G. Rasprostranennost' narushenii sna u zhitelei Chuvashii (dannye sploshnogo anketnogo oprosa). Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2011; 111 (6): 64–7. [in Russian]
12. Gafarov V.V., Pak V.A., Gagulin I.V., Gafarova A.V. Psikhologiia zdorov'ia naseleniia v Rossii. Novosibirsk: SO RAMN, 2002; s. 359. [in Russian]
13. Golenkov A.V., Poluektov M.G. Osobennosti i narusheniia sna v pozhilom i starcheskom vozraste. Klinicheskaia gerontologiia. 2012; 7–8: 8–13. [in Russian]
14. Brower KJ, McCammon RJ, Wojnar M et al. Prescription sleeping pills, insomnia, and suicidality in the National Comorbidity Survey Replication. J Clin Psychiatry 2011; 72 (4): 515–21.
15. Poluektov M.G. Klinicheskii algoritm diagnosticheskogo i lechebnogo vybora pri insomnii. Effektivnaia farmakoterapiia. 2013; 12: 22–8. [in Russian]
16. Ong JC, Arnedt JT, Gehrman PR. Insomnia diagnosis, assessment and evaluation. In: Kryger MH, Roth T, Dement WC (eds.) Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 785–93.
17. Poluektov MG. Insomnii. V kn.: Somnologiia i meditsina sna. Natsional'noe rukovodstvo pamiati A.M.Veina i Ia.I.Levina. Pod red. M.G.Poluektova. M.: Medforum, 2016; s. 298–318. [in Russian]
18. Morgenthaler T, Alessi C, Friedman L et al. Practice parameters for the use of actigraphy in the assessment of sleep and sleep disorders: an update for 2007. Sleep 2007; 30 (4): 519–29.
19. Magomedova K.A., Poluektov M.G. Primenenie aktigrafii dlia vyiavleniia narushenii sna u lits starshikh vozrastnykh grupp. Klinicheskaia gerontologiia. 2014; 20 (3–4): 35–8. [in Russian]
20. Kushida CA, Littner MR, Morgenthaler T et al. Practice parameters for the indications for polysomnography and related procedures: an update for 2005. Sleep 2005; 28 (4): 499–521.
21. Buysse DJ, Reynolds CF, Monk TH et al. The Pittsburgh Sleep Quality Index (PSQI): a new instrument for psychiatric research and practice. Psychiatry Res 1989; 28: 193–213.
22. Morin CM. Insomnia: Psychological assessment and management. New York: Guilford Press, 1993.
23. Espie CA, Inglis SJ, Harvey L, Tessier S. Insomniacs' attributions. psychometric properties of the Dysfunctional Beliefs and Attitudes about Sleep Scale and the Sleep Disturbance Questionnaire. J Psychosom Res 2000; 48 (2): 141–8.
24. Levin Ia.I., Eligulashvili T.S., Posokhov S.I. i dr. Farmakoterapiia insomnii: rol' Imovana. V kn.: Rasstroistva sna. Pod red. Iu.A.Aleksandrovskogo, A.M.Veina. SPb: Med. inform. agentstvo, 1995; s. 56–61. [in Russian]
25. Spielman A, Caruso L, Glovinsky P. A behavioral perspective on insomnia treatment. Psychiatric Clinic of North America 1987; 10: 541–53.
26. Perlis ML, Ellis JG, Kloss JD, Riemann DW. Etiology and Pathophysiology of Insomnia. In: Kryger MH, Roth T, Dement WC (eds.) Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 769–84.
27. Morin CM, Davidson JR, Beaulieu-Bonneau S. Cognitive Behavior Therapies for Insomnia I: Approaches and Efficacy. In: Kryger MH, Roth T, Dement WC (eds.). Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 804–13.
28. Zachariae R, Lyby MS, Ritterband LM, O'Toole MS. Efficacy of internet-delivered cognitive-behavioral therapy for insomnia: A systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev 2015; 30: 1–10.
29. Trauer JM, Qian MY, Doyle JS et al. Cognitive Behavioral Therapy for Chronic Insomnia: A systematic review and meta-analysis. Ann Intern Med 2015; 163 (3): 191–204.
30. Carson S, McDonagh MS, Thakurta S, Yen PY. Drug Class Review: Newer Drugs for Insomnia: Final Report Update 2 [Internet]. Portland (OR): Oregon Health & Science University. 2008.
31. Levin Ia.I. Klinicheskii opyt primeneniia zopiklona (Relakson) pri insomnii. Effektivnaia farmakoterapiia. 2011; 1: 14–20. [in Russian]
32. Strygin K.N., Levin Ia.I. Sovremennaia terapiia insomnii: rol' zopiklona. Nevrologiia i revmatologiia. 2010; 1: 48–52. [in Russian]
33. MacFarlane J, Morin CM, Montplaisir J. Hypnotics in insomnia: the experience of zolpidem. Clin Ther 2014; 36 (11): 1676–701.
34. Shmyrov V.I., Klochkova L.B. Otkrytoe mnogotsentrovoe issledovanie zolpidema (Ivadala) pri lechenii insomnii. Farmateka. 2001; 5: 32–43. [in Russian]
35. Levin Ia.I. Insomniia: klinicheskii opyt primeneniia zolpidema (Sanval). Nevrol. neiropsikhiatr. psikhosom. 2010; 3: 87–91. [in Russian]
36. Ancoli-Israel S, Richardson GS, Mangano RM et al. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med 2005; 6: 107–13.
37. Kales A, Manfredi RL, Vgontzas AN et al. Clonazepam: sleep laboratory study of efficacy and withdrawal. J Clin Psychopharmacol 1991; 11 (3): 189–93.
38. Dashti-Khavidaki S, Chamani N, Khalili H. Comparing effects of clonazepam and zolpidem on sleep quality of patients on maintenance hemodialysis. Iran J Kidney Dis 2011; 5 (6): 404–9.
39. Kok LP, Tsoi WF. Comparison of midazolam, diazepam and placebo in the treatment of insomnia. Singapore Med J 1986; 27 (3): 200–3.
40. Walsh JK, Roth T. Pharmacologic Treatment of Insomnia: Benzodiazepine Receptor Agonists. In: Kryger MH, Roth T, Dement WC (eds.) Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 832–41.
41. Montplaisir J, Hawa R, Moller H et al. Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement. Hum Psychopharmacol 2003; 18 (1): 29–38.
42. Wyatt JK, Dijk DJ, Ritz-de Cecco A et al. Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep 2006; 29 (5): 609–18.
43. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One 2013; 8 (5): e63773.
44. Costello RB, Lentino CV, Boyd CC et al. The effectiveness of melatonin for promoting healthy sleep: a rapid evidence assessment of the literature. Nutr J 2014; 13:106.
45. Poluektov M.G., Levin Ia.I., Boiko A.N. i dr. Rezul'taty rossiiskogo mul'titsentrovogo issledovaniia effektivnosti i bezopasnosti melaksena (melatonin) dlia lecheniia narushenii sna u patsientov s khronicheskoi tserebral'noi sosudistoi nedostatochnost'iu. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2012; 112 (9): 26–31. [in Russian]
46. Kovrov G.V., Agal'tsov M.V., Sukmarova Z.N. Effektivnost' melatonina prolongirovannogo vysvobozhdeniia pri pervichnykh narusheniiakh sna u patsientov starshe 55 let. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2016; 8 (2): 24–30. [in Russian]
47. Litvinenko I.V., Krasakov I.V., Tikhomirova O.V. Rasstroistva sna pri neoslozhnennoi dementsiei bolezni Parkinsona: rezul'taty kontroliruemogo sravnitel'nogo issledovaniia primeneniia melatonina i klonazepama. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2012; 112 (12): 26–30. [in Russian]
48. Fedorova N.V., Nikitina A.V., Gubanova E.V. Rol' melatonina v terapii pervichnykh narushenii sna u patsientov s bolezn'iu Parkinsona. Consilium Medicum. Neurology and Rheumatology (Suppl.). 2012; 2: 69–72. / [in Russian]
49. Glass JR, Sproule BA, Herrmann N, Busto UE. Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trial. J Clin Psychopharmacol 2008; 28 (2): 182–8.
50. Morin CM, Koetter U, Bastien C et al. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep 2005; 28 (11): 1465–71.
51. Smith GM, Smith PH. Effects of doxylamine and acetaminophen on postoperative sleep. Clin Pharmacol Ther 1985; 37 (5): 549–57.
52. Schadeck B, Chelly M, Amsellem D. et al. Comparative efficacy of doxylamine (15 mg ) and zolpidem (10 mg) for the treatment of common insomnia – a placebo-controlled study. La Semaine des hopitaux de Paris 1993; 72 (13–14): 428–39.
53. Madaeva I.M., Shevyrtalova O.N., Madaev V.V. Primenenie doksilamina pri insomnii u patsientov s arterial'noi gipertenziei. Sonsilium Medicum. 2009; 11 (9): 69–72. [in Russian]
54. Vande Griend JP, Anderson SL. Histamine-1 receptor antagonism for treatment of insomnia. J Am Pharm Assoc (2003) 2012; 52 (6): e210–9.
55. Krystal AD. Pharmacologic treatment of insomnia: other medications. In: Kryger MH, Roth T., Dement W.C. (eds.) Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016; p. 842–54.
56. Tassniyom K, Paholpak S, Tassniyom S, Kiewyoo J. Quetiapine for primary insomnia: a double blind, randomized controlled trial. J Med Assoc Thai 2010; 93 (6): 729–34.
57. Brower KJ, Myra Kim H, Strobbe S et al. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res 2008; 32 (8): 1429–38.
58. Fernández-San-Martín MI, Masa-Font R, Palacios-Soler L et al. Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med 2010; 11 (6): 505–11.
59. Douros A, Bronder E, Andersohn F et al. Herb-induced liver injury in the Berlin case-control surveillance study. Int J Mol Sci 2016; 17 (1): pii: E114.
60. Kolla BP, Lovely JK, Mansukhani MP, Morgenthaler TI. Zolpidem is independently associated with increased risk of inpatient falls. J Hosp Med 2013; 8 (1): 1–6.
61. Madjunkova S, Maltepe C, Koren G. The delayed-release combination of doxylamine and pyridoxine (DiclegisR/DiclectinR) for the treatment of nausea and vomiting of pregnancy. Paediatr Drugs 2014; 16 (3): 199–211.
Авторы
М.Г.Полуэктов*, Р.В.Бузунов, В.М.Авербух, Е.В.Вербицкий, А.В.Захаров, И.А.Кельмансон, Е.А.Корабельникова, А.Ю.Литвин, И.М.Мадаева, А.Д.Пальман, Ю.Ю.Русецкий, К.Н.Стрыгин, Э.З.Якупов
Общероссийская общественная организация Российское общество сомнологов. 123290, Россия, Москва, 1-й Магистральный тупик, д. 5А
*polouekt@mail.ru
Task Force of Sientific Council of All-Russian Public Organization "Russian Society of Sleep Medicine". 123290, Russian Federation, Moscow, 1-i Magistral'nyi tupik, d. 5A
*polouekt@mail.ru
Общероссийская общественная организация Российское общество сомнологов. 123290, Россия, Москва, 1-й Магистральный тупик, д. 5А
*polouekt@mail.ru
________________________________________________
Task Force of Sientific Council of All-Russian Public Organization "Russian Society of Sleep Medicine". 123290, Russian Federation, Moscow, 1-i Magistral'nyi tupik, d. 5A
*polouekt@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.